Integrase Inhibitors Market, By Drug (Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, and Others ), By Route of Administration, By Distribution Channel, By Geography

PUBLISHED: October 30, 2023

PAGES: 150 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

The global integrase inhibitors market size was valued at US$ 14.7 billion in 2023 and is expected US$ 21.7 billion by 2030 is expected to grow at a compound annual growth rate (CAGR) of 5.7% from 2023 to 2030.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 14.7 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.70%	2030 Value Projection:	US$ 21.7 Bn

Figure 1. Global Integrase Inhibitors Market Share (%), By Region, 2023

Integrase inhibitors are a relatively new class of antiretroviral drugs used for the treatment of HIV/AIDS. They work by specifically inhibiting HIV integrase, a retroviral enzyme that is essential for the replication of HIV's genome in host cells. Integrase inhibitors prevent integration of HIV viral DNA into the chromosomal DNA of the infected cells, thus blocking the propagation of new HIV virions. The first generation integrase inhibitor raltegravir was approved in 2007, offering a novel mechanism of action in suppressing HIV replication. It demonstrated high efficacy and good tolerability in clinical trials. Since then, newer generations of integrase inhibitors like elvitegravir and dolutegravir have been developed and approved. These agents have shown improved effectiveness and tolerability profiles over existing anti-HIV therapies. The introduction of integrase inhibitors has significantly expanded treatment options for HIV management. Integrase Inhibitors are primarily used in the treatment of HIV/AIDS by inhibiting the activity of the viral enzyme called integrase, thereby preventing the integration of the viral DNA into the host cell's DNA.

Market Dynamics:

The global integrase inhibitors market growth is primarily driven by the rising HIV/AIDS disease burden worldwide, increasing adoption of antiretroviral treatment (ART) for HIV, and robust product pipeline with introduction of newer and improved integrase inhibitor drugs. Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety of integrase inhibitors are major factors expected to drive growth of the global integrase inhibitors market during the forecast period. Favorable government initiatives in developed nations regarding coverage of antiretroviral therapy presents lucrative opportunities. However, the market growth can be negatively impacted by the emergence of drug-resistant strains of HIV and high costs of integrase inhibitor therapies. Key market players are engaged in R&D of long-acting injectable/oral formulations to increase adherence to treatment and drive revenue opportunities.

Key features of the study:

This report provides in-depth analysis of the global integrase inhibitors market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global integrase inhibitors market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Gilead Sciences, ViiV Healthcare group, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen Pharmaceuticals, Inc., Theratechnologies Inc., Shionogi & Co., Ltd., and Viatris Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global integrase inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global integrase inhibitors market.

Detailed Segmentation:

By Drug:
- Raltegravir
- Dolutegravir
- Elvitegravir
- Bictegravir
- Others (Cabotegravir, etc.)
By Route of Administration:
- Oral
- Intravenous
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Gilead Sciences
- ViiV Healthcare group
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc.
- Janssen Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Shionogi & Co., Ltd.
- Viatris Inc.

Product Code: CMI6023

Market Dynamics
- Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety
- High Treatment Costs, Side Effects and Safety Concerns
- Integrase Inhibitors with improved therapeutic profiles.
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Integrase Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Integrase Inhibitors Market, By Drug, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Raltegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Dolutegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Elvitegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Bictegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Others (Cabotegravir, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

6. Global Integrase Inhibitors Market, By Route of Administration, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

7. Global Integrase Inhibitors Market, By Distribution Channel, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global Integrase Inhibitors Market, By Region, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
India
China
Japan
Australia
ASEAN
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 - 2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
ViiV Healthcare group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Janssen Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Theratechnologies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Shionogi & Co., Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views